RA Misc: Ofatumumab

Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

Image result for ofatumumabImage result for ofatumumab

To investigate the safety and efficacy of ofatumumab, a novel human anti‐CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to ≥1 disease‐modifying…
onlinelibrary.wiley.com

Ofatumumab for rheumatoid arthritis

Image result for ofatumumab

This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the benefits and harms of ofatumumab in reducing disease activity, pain, and improving function in people…
onlinelibrary.wiley.com

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Image result for ofatumumab

Objectives To investigate the safety of ofatumumab retreatment in rheumatoid arthritis. Methods Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatme…
journals.plos.org

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Objective. To investigate the safety and tolerability of a single subcutaneous (SC) dose of ofatumumab, a fully human anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis (RA) taking background methotrexate (MTX). Secondary objectives included characterizing pharmacokinetics and phar…
jrheum.org

A subcutaneous 30mg dose of Ofatumumab provides 2 months of profound B-cell depletion, without troublesome infusion reactions. If clinical efficacy pans out, RA treatment just became effective, safe, convenient and super-cheap!